-
1
-
-
84980396108
-
ESC Scientific Document Group. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC
-
Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJS, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P; ESC Scientific Document Group. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129–2200.
-
(2016)
Eur Heart J
, vol.37
, pp. 2129-2200
-
-
Ponikowski, P.1
Voors, A.A.2
Anker, S.D.3
Bueno, H.4
Cleland, J.G.5
Coats, A.6
Falk, V.7
Gonzalez-Juanatey, J.R.8
Harjola, V.P.9
Jankowska, E.A.10
Jessup, M.11
Linde, C.12
Nihoyannopoulos, P.13
Parissis, J.T.14
Pieske, B.15
Riley, J.P.16
Rosano, G.17
Ruilope, L.M.18
Ruschitzka, F.19
Rutten, F.H.20
Van Der Meer, P.21
more..
-
2
-
-
84880922018
-
Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis
-
Brown NJ. Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis. Nat Rev Nephrol. 2013;9:459–469.
-
(2013)
Nat Rev Nephrol
, vol.9
, pp. 459-469
-
-
Brown, N.J.1
-
3
-
-
0033517302
-
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators
-
Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709–717.
-
(1999)
N Engl J Med
, vol.341
, pp. 709-717
-
-
Pitt, B.1
Zannad, F.2
Remme, W.J.3
Cody, R.4
Castaigne, A.5
Perez, A.6
Palensky, J.7
Wittes, J.8
-
4
-
-
0037417252
-
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction
-
Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309–1321.
-
(2003)
N Engl J Med
, vol.348
, pp. 1309-1321
-
-
Pitt, B.1
Remme, W.2
Zannad, F.3
Neaton, J.4
Martinez, F.5
Roniker, B.6
Bittman, R.7
Hurley, S.8
Kleiman, J.9
Gatlin, M.10
-
5
-
-
84879748718
-
A novel paradigm for heart failure with preserved ejection fraction: Comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation
-
Paulus WJ, Tschope C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62:263–271.
-
(2013)
J am Coll Cardiol
, vol.62
, pp. 263-271
-
-
Paulus, W.J.1
Tschope, C.2
-
6
-
-
84898713808
-
Spironolactone for heart failure with preserved ejection fraction
-
Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Harty B, Heitner JF, Kenwood CT, Lewis EF, O’Meara E, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, Yang S, McKinlay SM. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370:1383–1392.
-
(2014)
N Engl J Med
, vol.370
, pp. 1383-1392
-
-
Pitt, B.1
Pfeffer, M.A.2
Assmann, S.F.3
Boineau, R.4
Anand, I.S.5
Claggett, B.6
Clausell, N.7
Desai, A.S.8
Diaz, R.9
Fleg, J.L.10
Gordeev, I.11
Harty, B.12
Heitner, J.F.13
Kenwood, C.T.14
Lewis, E.F.15
O’Meara, E.16
Probstfield, J.L.17
Shaburishvili, T.18
Shah, S.J.19
Solomon, S.D.20
Sweitzer, N.K.21
Yang, S.22
McKinlay, S.M.23
more..
-
7
-
-
84925581450
-
Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial
-
Pfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Heitner JF, Lewis EF, O’Meara E, Rouleau JL, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, McKinlay SM, Pitt B. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation. 2015;131:34–42.
-
(2015)
Circulation
, vol.131
, pp. 34-42
-
-
Pfeffer, M.A.1
Claggett, B.2
Assmann, S.F.3
Boineau, R.4
Anand, I.S.5
Clausell, N.6
Desai, A.S.7
Diaz, R.8
Fleg, J.L.9
Gordeev, I.10
Heitner, J.F.11
Lewis, E.F.12
O’Meara, E.13
Rouleau, J.L.14
Probstfield, J.L.15
Shaburishvili, T.16
Shah, S.J.17
Solomon, S.D.18
Sweitzer, N.K.19
McKinlay, S.M.20
Pitt, B.21
more..
-
8
-
-
84894277519
-
Renal impairment, worsening renal function, and outcome in patients with heart failure: An updated meta-analysis
-
Damman K, Valente MA, Voors AA, O’Connor CM, van Veldhuisen DJ, Hillege HL. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J. 2014;35:455–469.
-
(2014)
Eur Heart J
, vol.35
, pp. 455-469
-
-
Damman, K.1
Valente, M.A.2
Voors, A.A.3
O’Connor, C.M.4
Van Veldhuisen, D.J.5
Hillege, H.L.6
-
9
-
-
84978970368
-
Prevalence and prognostic impact of kidney disease on heart failure patients
-
Lofman I, Szummer K, Hagerman I, Dahlstrom U, Lund LH, Jernberg T. Prevalence and prognostic impact of kidney disease on heart failure patients. Open Heart. 2016;3:e000324.
-
(2016)
Open Heart
, vol.3
-
-
Lofman, I.1
Szummer, K.2
Hagerman, I.3
Dahlstrom, U.4
Lund, L.H.5
Jernberg, T.6
-
10
-
-
67651048925
-
Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: A randomized controlled trial
-
Edwards NC, Steeds RP, Stewart PM, Ferro CJ, Townend JN. Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial. J Am Coll Cardiol. 2009;54:505–512.
-
(2009)
J am Coll Cardiol
, vol.54
, pp. 505-512
-
-
Edwards, N.C.1
Steeds, R.P.2
Stewart, P.M.3
Ferro, C.J.4
Townend, J.N.5
-
11
-
-
78049273225
-
The Swedish Web-system for enhancement and development of evidence-based care in heart disease evaluated according to recommended therapies (SWEDEHEART)
-
Jernberg T, Attebring MF, Hambraeus K, Ivert T, James S, Jeppsson A, Lagerqvist B, Lindahl B, Stenestrand U, Wallentin L. The Swedish Web-system for enhancement and development of evidence-based care in heart disease evaluated according to recommended therapies (SWEDEHEART). Heart. 2010;96:1617–1621.
-
(2010)
Heart
, vol.96
, pp. 1617-1621
-
-
Jernberg, T.1
Attebring, M.F.2
Hambraeus, K.3
Ivert, T.4
James, S.5
Jeppsson, A.6
Lagerqvist, B.7
Lindahl, B.8
Stenestrand, U.9
Wallentin, L.10
-
12
-
-
84896767746
-
The Chronic Kidney Disease Epidemiology Collaboration equation outperforms the Modification of Diet in Renal Disease equation for estimating glomerular filtration rate in chronic systolic heart failure
-
Valente MA, Hillege HL, Navis G, Voors AA, Dunselman PH, van Veldhuisen DJ, Damman K. The Chronic Kidney Disease Epidemiology Collaboration equation outperforms the Modification of Diet in Renal Disease equation for estimating glomerular filtration rate in chronic systolic heart failure. Eur J Heart Fail. 2014;16:86–94.
-
(2014)
Eur J Heart Fail
, vol.16
, pp. 86-94
-
-
Valente, M.A.1
Hillege, H.L.2
Navis, G.3
Voors, A.A.4
Dunselman, P.H.5
Van Veldhuisen, D.J.6
Damman, K.7
-
13
-
-
84895894249
-
Comparison of random forest and parametric imputation models for imputing missing data using MICE: A CALIBER study
-
Shah AD, Bartlett JW, Carpenter J, Nicholas O, Hemingway H. Comparison of random forest and parametric imputation models for imputing missing data using MICE: a CALIBER study. Am J Epidemiol. 2014;179:764–774.
-
(2014)
Am J Epidemiol
, vol.179
, pp. 764-774
-
-
Shah, A.D.1
Bartlett, J.W.2
Carpenter, J.3
Nicholas, O.4
Hemingway, H.5
-
14
-
-
78650399880
-
Eplerenone in patients with systolic heart failure and mild symptoms
-
Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11–21.
-
(2011)
N Engl J Med
, vol.364
, pp. 11-21
-
-
Zannad, F.1
McMurray, J.J.2
Krum, H.3
Van Veldhuisen, D.J.4
Swedberg, K.5
Shi, H.6
Vincent, J.7
Pocock, S.J.8
Pitt, B.9
-
15
-
-
85040602547
-
ESC Scientific Document Group. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with STsegment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)
-
Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A, Lenzen MJ, Prescott E, Roffi M, Valgimigli M, Varenhorst C, Vranckx P, Widimsky P; ESC Scientific Document Group. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with STsegment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39:119–177.
-
(2018)
Eur Heart J
, vol.39
, pp. 119-177
-
-
Ibanez, B.1
James, S.2
Agewall, S.3
Antunes, M.J.4
Bucciarelli-Ducci, C.5
Bueno, H.6
Caforio, A.7
Crea, F.8
Goudevenos, J.A.9
Halvorsen, S.10
Hindricks, G.11
Kastrati, A.12
Lenzen, M.J.13
Prescott, E.14
Roffi, M.15
Valgimigli, M.16
Varenhorst, C.17
Vranckx, P.18
Widimsky, P.19
-
16
-
-
84885181092
-
Use of aldosterone antagonists at discharge after myocardial infarction: Results from the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network (ACTION) Registry-Get with the Guidelines (GWTG)
-
Rao KK, Enriquez JR, de Lemos JA, Alexander KP, Chen AY, McGuire DK, Fonarow GC, Das SR. Use of aldosterone antagonists at discharge after myocardial infarction: results from the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network (ACTION) Registry-Get with the Guidelines (GWTG). Am Heart J. 2013;166: 709–715.
-
(2013)
Am Heart J
, vol.166
, pp. 709-715
-
-
Rao, K.K.1
Enriquez, J.R.2
De Lemos, J.A.3
Alexander, K.P.4
Chen, A.Y.5
McGuire, D.K.6
Fonarow, G.C.7
Das, S.R.8
-
17
-
-
85000761501
-
Mineralocorticoid receptor antagonists for heart failure: Systematic review and meta-analysis
-
Berbenetz NM, Mrkobrada M. Mineralocorticoid receptor antagonists for heart failure: systematic review and meta-analysis. BMC Cardiovasc Disord. 2016;16:246.
-
(2016)
BMC Cardiovasc Disord
, vol.16
, pp. 246
-
-
Berbenetz, N.M.1
Mrkobrada, M.2
-
18
-
-
85017404025
-
Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, midrange and reduced ejection fraction: An analysis of the ESC Heart Failure Long- Term Registry
-
Chioncel O, Lainscak M, Seferovic PM, Anker SD, Crespo-Leiro MG, Harjola VP, Parissis J, Laroche C, Piepoli MF, Fonseca C, Mebazaa A, Lund L, Ambrosio GA, Coats AJ, Ferrari R, Ruschitzka F, Maggioni AP, Filippatos G. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, midrange and reduced ejection fraction: an analysis of the ESC Heart Failure Long- Term Registry. Eur J Heart Fail. 2017;19:1574–1585.
-
(2017)
Eur J Heart Fail
, vol.19
, pp. 1574-1585
-
-
Chioncel, O.1
Lainscak, M.2
Seferovic, P.M.3
Anker, S.D.4
Crespo-Leiro, M.G.5
Harjola, V.P.6
Parissis, J.7
Laroche, C.8
Piepoli, M.F.9
Fonseca, C.10
Mebazaa, A.11
Lund, L.12
Ambrosio, G.A.13
Coats, A.J.14
Ferrari, R.15
Ruschitzka, F.16
Maggioni, A.P.17
Filippatos, G.18
-
19
-
-
84875513232
-
Aldosterone antagonists and outcomes in real-world older patients with heart failure and preserved ejection fraction
-
Patel K, Fonarow GC, Kitzman DW, Aban IB, Love TE, Allman RM, Gheorghiade M, Ahmed A. Aldosterone antagonists and outcomes in real-world older patients with heart failure and preserved ejection fraction. JACC Heart Fail. 2013;1:40–47.
-
(2013)
JACC Heart Fail
, vol.1
, pp. 40-47
-
-
Patel, K.1
Fonarow, G.C.2
Kitzman, D.W.3
Aban, I.B.4
Love, T.E.5
Allman, R.M.6
Gheorghiade, M.7
Ahmed, A.8
-
20
-
-
85014030240
-
Registry-based pragmatic trials in heart failure: Current experience and future directions
-
Lund LH, Oldgren J, James S. Registry-based pragmatic trials in heart failure: current experience and future directions. Curr Heart Fail Rep. 2017;14:59–70.
-
(2017)
Curr Heart Fail Rep
, vol.14
, pp. 59-70
-
-
Lund, L.H.1
Oldgren, J.2
James, S.3
-
21
-
-
84960104469
-
Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction
-
Solomon SD, Claggett B, Lewis EF, Desai A, Anand I, Sweitzer NK, O’Meara E, Shah SJ, McKinlay S, Fleg JL, Sopko G, Pitt B, Pfeffer MA. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J. 2016;37:455–462.
-
(2016)
Eur Heart J
, vol.37
, pp. 455-462
-
-
Solomon, S.D.1
Claggett, B.2
Lewis, E.F.3
Desai, A.4
Anand, I.5
Sweitzer, N.K.6
O’Meara, E.7
Shah, S.J.8
McKinlay, S.9
Fleg, J.L.10
Sopko, G.11
Pitt, B.12
Pfeffer, M.A.13
-
22
-
-
85016811660
-
Associations with and prognostic impact of chronic kidney disease in heart failure with preserved, mid-range, and reduced ejection fraction
-
Lofman I, Szummer K, Dahlstrom U, Jernberg T, Lund LH. Associations with and prognostic impact of chronic kidney disease in heart failure with preserved, mid-range, and reduced ejection fraction. Eur J Heart Fail. 2017;19:1606–1614.
-
(2017)
Eur J Heart Fail
, vol.19
, pp. 1606-1614
-
-
Lofman, I.1
Szummer, K.2
Dahlstrom, U.3
Jernberg, T.4
Lund, L.H.5
-
23
-
-
11844302228
-
Heart failure after myocardial infarction: Clinical presentation and survival
-
Hellermann JP, Jacobsen SJ, Redfield MM, Reeder GS, Weston SA, Roger VL. Heart failure after myocardial infarction: clinical presentation and survival. Eur J Heart Fail. 2005;7:119–125.
-
(2005)
Eur J Heart Fail
, vol.7
, pp. 119-125
-
-
Hellermann, J.P.1
Jacobsen, S.J.2
Redfield, M.M.3
Reeder, G.S.4
Weston, S.A.5
Roger, V.L.6
-
24
-
-
84863221796
-
For the JCARE-CARD Investigators. Mode of death in patients with heart failure and reduced vs. Preserved ejection fraction
-
Hamaguchi S, Kinugawa S, Sobirin MA, Goto D, Tsuchihashi-Makaya M, Yamada S, Yokoshiki H, Tsutsui H; for the JCARE-CARD Investigators. Mode of death in patients with heart failure and reduced vs. preserved ejection fraction. Circ J. 2012;76:1662–1669.
-
(2012)
Circ J
, vol.76
, pp. 1662-1669
-
-
Hamaguchi, S.1
Kinugawa, S.2
Sobirin, M.A.3
Goto, D.4
Tsuchihashi-Makaya, M.5
Yamada, S.6
Yokoshiki, H.7
Tsutsui, H.8
-
25
-
-
84860309326
-
Eplerenone and atrial fibrillation in mild systolic heart failure: Results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study
-
Swedberg K, Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Shi H, Vincent J, Pitt B; Investigators EMPHASIS-HF Study Investigators. Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study. J Am Coll Cardiol. 2012;59:1598–1603.
-
(2012)
J am Coll Cardiol
, vol.59
, pp. 1598-1603
-
-
Swedberg, K.1
Zannad, F.2
McMurray, J.J.3
Krum, H.4
Van Veldhuisen, D.J.5
Shi, H.6
Vincent, J.7
Pitt, B.8
-
26
-
-
0242366540
-
Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats
-
Blasi ER, Rocha R, Rudolph AE, Blomme EA, Polly ML, McMahon EG. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int. 2003;63:1791–1800.
-
(2003)
Kidney Int
, vol.63
, pp. 1791-1800
-
-
Blasi, E.R.1
Rocha, R.2
Rudolph, A.E.3
Blomme, E.A.4
Polly, M.L.5
McMahon, E.G.6
-
27
-
-
84969808857
-
Effects of mineralocorticoid receptor antagonists on left ventricular mass in chronic kidney disease patients: A systematic review and meta-analysis
-
Lu R, Zhang Y, Zhu X, Fan Z, Zhu S, Cui M, Zhang Y, Tang F. Effects of mineralocorticoid receptor antagonists on left ventricular mass in chronic kidney disease patients: a systematic review and meta-analysis. Int Urol Nephrol. 2016;48:1499–1509.
-
(2016)
Int Urol Nephrol
, vol.48
, pp. 1499-1509
-
-
Lu, R.1
Zhang, Y.2
Zhu, X.3
Fan, Z.4
Zhu, S.5
Cui, M.6
Zhang, Y.7
Tang, F.8
-
28
-
-
84893842735
-
Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients
-
Matsumoto Y, Mori Y, Kageyama S, Arihara K, Sugiyama T, Ohmura H, Yakushigawa T, Sugiyama H, Shimada Y, Nojima Y, Shio N. Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients. J Am Coll Cardiol. 2014;63:528–536.
-
(2014)
J am Coll Cardiol
, vol.63
, pp. 528-536
-
-
Matsumoto, Y.1
Mori, Y.2
Kageyama, S.3
Arihara, K.4
Sugiyama, T.5
Ohmura, H.6
Yakushigawa, T.7
Sugiyama, H.8
Shimada, Y.9
Nojima, Y.10
Shio, N.11
-
29
-
-
84886023778
-
Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: Analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure)
-
Eschalier R, McMurray JJ, Swedberg K, van Veldhuisen DJ, Krum H, Pocock SJ, Shi H, Vincent J, Rossignol P, Zannad F, Pitt B; EMPHASIS-HF Investigators. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure). J Am Coll Cardiol. 2013;62:1585–1593.
-
(2013)
J am Coll Cardiol
, vol.62
, pp. 1585-1593
-
-
Eschalier, R.1
McMurray, J.J.2
Swedberg, K.3
Van Veldhuisen, D.J.4
Krum, H.5
Pocock, S.J.6
Shi, H.7
Vincent, J.8
Rossignol, P.9
Zannad, F.10
Pitt, B.11
-
30
-
-
84868574835
-
Influence of baseline and worsening renal function on efficacy of spironolactone in patients with severe heart failure: Insights from RALES (Randomized Aldactone Evaluation Study)
-
Vardeny O, Wu DH, Desai A, Rossignol P, Zannad F, Pitt B, Solomon SD; RALES Investigators. Influence of baseline and worsening renal function on efficacy of spironolactone in patients with severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study). J Am Coll Cardiol. 2012;60:2082–2089.
-
(2012)
J am Coll Cardiol
, vol.60
, pp. 2082-2089
-
-
Vardeny, O.1
Wu, D.H.2
Desai, A.3
Rossignol, P.4
Zannad, F.5
Pitt, B.6
Solomon, S.D.7
-
31
-
-
84896109810
-
Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: Results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF)
-
Rossignol P, Dobre D, McMurray JJ, Swedberg K, Krum H, van Veldhuisen DJ, Shi H, Messig M, Vincent J, Girerd N, Bakris G, Pitt B, Zannad F. Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). Circ Heart Fail. 2014;7:51–58.
-
(2014)
Circ Heart Fail
, vol.7
, pp. 51-58
-
-
Rossignol, P.1
Dobre, D.2
McMurray, J.J.3
Swedberg, K.4
Krum, H.5
Van Veldhuisen, D.J.6
Shi, H.7
Messig, M.8
Vincent, J.9
Girerd, N.10
Bakris, G.11
Pitt, B.12
Zannad, F.13
|